> **Sanofi-Synthelado**
>
> **SL77.0499-10 (ALFUZOSIN)**
>
> **Bibliography**

1.  Malik M. Problems of heart rate correction in assessment of
    drug-induced QT interval prolongation. J Cardiovasc Electrophysiol
    2001; 12:411-20.

2.  Hnatkova K, Malik M. \"Optimum\" formulae for heart rate correction
    of the QT interval. PACE 1999; 22:1683-7.

3.  Badilini F, Maison-Blanche P, Childers R, Coumel P. QT interval
    analysis on ambulatory ECG recordings: a selective beat averaging
    approach. Med Biol Eng Comput 1998; 36:1-10.

4.  Extramiana F, Maison-Blanche P, Badilini F, Pinoteau J, Deseo T,
    Coumel P. Circadian modulation of QT rate dependence in healthy
    volunteers: gender and age differences. J Electrocardiol 1999;
    32:33-43.

5.  Preliminary concept paper: The clinical evaluation of QT/QTc
    interval prolongation and proarrhythmic potential for
    non-antiarrhythmic drugs. Revised version 6 February 2003.

6.  USFDA: summary basis of approval to NDA 21-085, sup 10 for
    moxifloxacin - Approved 27 April 2001. (Not provided).

7.  Rhodes PR, Krogh RH, Bruskewitz RC. Impact of drug therapy on benign
    prostatic hyperplasia-specific quality of life. Urology 1999;
    53:1090-8.

8.  Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Alfuzosin for
    treatment of benign prostatic hypertrophy. Lancet 1991; 337:1457-61.

9.  Teillac P, Delauche-Cavallier MC, Attali P, et al. Urinary flow
    rates in patients with benign prostatic hypertrophy following
    treatment with alfuzosin, Br J Urol 1992; 70:58-64.

10. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Long-term
    treatment of benign prostatic hyperplasia with alfuzosin: a 12-18
    month assessment. Br J Urol 1993; 72:615-20.

11. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Long-term
    treatment of benign prostatic hyperplasia with alfuzosin: a 24-30
    month survey. Br J Urol 1993; 74:579-84.

12. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC, et
    al. Efficacy and safety of sustained release alfuzosin 5 mg in
    patients with benign prostatic hyperplasia. Eur Urol 1997; 31:190-8.

13. Debruyne FMJ, Jardin A, Colloi D, et al. Sustained-release
    alfuzosin, finasteride and the combination of both in the treatment
    of benign prostatic hyperplasia. Eur Urol 1998; 34:169-75.

14. McNeill SA, Daruwala PD, Mitchell IDC, et al. Sustained-release
    alfuzosin and trial without catheter after acute urinary retention:
    a prospective, placebo‑controlled trial. BJU Int 1999; 84:622-7.

15. *Physicians\'s Desk Reference 2003*, Hytrin Monographs.

16. *Physicians\'s Desk Reference 2003*, Cardura.

17. *Physicians\'s Desk Reference 2003*, Flomax.

18. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: Techniques
    and limitations. Am J Cardiol 1993;72:17B-22B.

19. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch
    C, et al. The potential for QT prolongation and proarrhythmia by
    non-antiarrhythmic drugs: Clinical and regulatory implications.
    Report on a policy conference of the European Society of Cardiology.
    Eur Heart J 2000; 21:1216-31.

20. Malik M, Camm AJ. Evaluation of drug-induced QT interval
    prolongation. Implications for drug approval and labelling. Drug
    Safety 2001; 24(5):323-51.

21. Malik M. The imprecision heart rate correction may lead to
    artificial observations of drug induced QT interval changes. PACE
    2002; 25(2):209-16.

22. Aytemir K, Maarouf N, Gallagher MM, Yap YG, Waktare JEP, Malik M.

    a.  Comparison of formulae for heart rate correction of QT interval
        in exercise electrocardiograms. PACE 1999; 22:1397-1401.

23. Bonate PL, Russell T. Assessment of QTc prolongation for
    non-cardiac-related drugs from a drug development perspective. J
    Clin Pharmacol 1999; 39:349-58.

24. NDA 20-919: Zeldox (ziprasidone mesylate IM, Pfizer.) Briefing
    information. Pfizer. 15 Feb 2001
    <http://www.fda.gov/ohrms/dockets/ac/01/briefing/3685b2.htm>. (Not
    provided).

25. Ketek (telithromycine) Briefing Information, Aventis. 26 April 2001
    <http://www.fda.gov/ohrms/dockets/ac/01/briefing/3746b1.htm>. (Not
    provided).

26. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation
    between QT and RR intervals is highly individual among healthy
    subjects: implications for heart rate correction of the QT interval.
    Heart 2002; 87:220-8.

27. Moss AJ, Zareba W, Benhorin J, Couderc JP, Kennedy H,
    Locati‑Heilbron E, Maison‑Blanche P. ISHNE guidelines for
    electrocardiographic evaluation of drug‑related QT prolongation and
    other alterations in ventricular repolarization: task force summary.
    A report of the Task Force of the International Society for Holter
    and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular
    Repolarization. ANE 2001; 6(4):333-41.

28. Goodman DB.

    a.  Continuous 12-lead ECG recording. Analysis of digital ECG data.
        What can you do with the digitized ECG waveform that you cannot
        do with a paper ECG record?

    b.  Public presentation at FDA ECG data standards meeting (November
        2001)

29. <http://www.fda.gov/cder/regulatory/ersr/Goodman%5B1>\].ppt

30. Molnar J, Weiss J, Zhang F, Rosenthal JE. Evaluation of five QT
    correction formulas using a software-assisted method of continuous
    QT measurement from 24-hour Holter recordings. Am J Cardiol 1996;
    78:920-6.

31. Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the
    electrocardiogram. Circulation 1952; 6:378-88.

32. Hoffman BB. Catecholamines, sympathomimetic drugs, and adrenergic
    receptor antagonists. In: Hardman JG, Limbird LE Gilman AG, editors.
    Goodman & Gilman\'s The pharmacological basis of therapeutics,
    10^th^ ed. New York: McGraw‑Hill; 2001. p.215-68.

33. Stinson JC, Pears JS, Williams AJ, Campbell RWF. Use of 24 h
    ambulatory ECG recordings in the assessment of new chemical entities
    in healthy volunteers. Br J Clin Pharmacol 1995; 39:651-6.

34. Lukacs B, Blondin P, MacCarthy C, Du Boys B, Grippon P, Lassale C.
    Safety profile of 3 months\' therapy with alfuzosin in 13,389
    patients suffering from benign prostatic hypertrophy. Eur Urol 1996;
    29: 29-35.

35. Shah RR. The significance of QT interval in drug development. Br J
    Clin Pharmacol 2002; 54:188-202.